APRE
Aprea Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About APRE
Aprea Therapeutics, Inc.
A biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways
3805 Old Easton Road, Doylestown, Pennsylvania 18902
--
Aprea Therapeutics, Inc., was incorporated under the laws of the State of Delaware in May 2019. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing novel cancer therapies that reactivate mutant p53 tumor suppressor proteins.
Company Financials
EPS
APRE has released its 2025 Q3 earnings. EPS was reported at -0.47, versus the expected -0.1, missing expectations. The chart below visualizes how APRE has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
APRE has released its 2025 Q3 earnings report, with revenue of 1.85K, reflecting a YoY change of -99.48%, and net profit of -2.97M, showing a YoY change of 21.44%. The Sankey diagram below clearly presents APRE's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
